When every minute counts - MBT Sepsityper® with new, rapid workflow and improved formulation

For direct pathogen identification from positive blood culture bottles


Sepsis is a clinical syndrome that complicates severe infection. It is characterized by the cardinal signs of inflammation occurring in tissues that are remote from the infection.

Bruker’s Sepsityper solution is performed in conjunction with the Bruker MALDI Biotyper System; it is IVD-CE approved and is a very cost-effective alternative to molecular solutions.



The impact of sepsis on public healthcare

There is a high frequency of sepsis in European Intensive Care Units (ICUs) with 35% of patients having sepsis at some point of their ICU stay (Vincent JL et al. Crit Care Med 2006 34:344-353). Extrapolating from treated incidence rates in the United States, estimates go up to 19 million cases worldwide per year. The true incidence is presumably higher.

Mortality rates of sepsis are high and treatment of sepsis is very expensive. “Administration of an antimicrobial effective for isolated or suspected pathogens within the first hour of documented hypotension was associated with a survival rate of 79.9%. Each hour of delay in antimicrobial administration over the ensuing 6 hours was associated with an average decrease in survival of 7.6%.” (Kumar A et al. Crit Care Med 2006 34:1589-1596).

Whilst a broad-spectrum antibiotic is the first step in treating sepsis patients, in a high portion of cases (more than 75% of cases*) an early ID would enable a change in therapy hence lowering mortality rates, decreasing treatment costs and improving patient outcome. (*Stoneking LR, The Journal of Emergency Medicine, Vol. 44, No. 1, pp. 1–8, 2013)

Fast identification of pathogens with the MBT Sepsityper IVD Kit

Save time for your critical ICU patients. Bruker‘s MBT Sepsityper IVD Kit for fast isolation of microorganisms from positive blood cultures enables fast and reliable species identification from positive blood cultures. By using the new workflow the hands-on-time is less than 10 minutes hence the overall time until identification is 15-20 minutes after positive blood culture alert.

Using this kit in your mass spectrometry identification workflow reduces the turnaround time provided by traditional positive blood culture identification workflows by up to 24 hours by eliminating the time-consuming step of culturing the microorganisms. Identification results can therefore be reported significantly more quickly to ICU consultants compared to traditional methods.

Mass spectra from blood cultures are not 1:1 comparable with spectra from other cultures. Bruker has therefore developed the dedicated MBT Compass IVD Sepsityper Module. The modified processing of measured mass spectra results in higher sensitivity than regular spectra processing, without loss of specificity.

MBT Sepsityper enables faster results which physicians can act upon to manage blood stream infections, engage in the fight against resistance, and improve patient outcomes. The advantages of the MBT Sepsityper IVD Kit are illustrated in a case study from the Royal Bolton Hospital (UK), explaining how working with Bruker’s Sepsityper solution has transformed the outcome for sepsis patients, and has resulted in huge cost savings for the hospital.  

Subsequent beta-lactamase activity detection

The bacterial cells isolated from the positively flagged blood culture, using the rapid Sepsityper workflow, can conveniently be used in the MBT STAR-BL IVD assays for beta-lactamase activity detection.
The MBT STAR-Carba IVD Kit, in conjunction with the MBT STAR-BL IVD software module, allows rapid identification of bacteria and detection of carbapenemase activity in one workflow. Similarly, by means of the easy to use MBT STAR-Cepha IVD Kit cephalosporinase activity towards 3rd generation cephalosporins can be detected within one hour from a positive blood culture alert.

Read more in a case study about the Bologna Workflow, for microorganism identification and antimicrobial susceptibility testing after positive blood culture.